List of works - Matthew Jenner

A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value

scientific article published on 8 July 2010

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).

scientific article

Advances in oral therapy for multiple myeloma.

scientific article

Deletions of CDKN2C in multiple myeloma: biological and clinical implications

scientific article published on October 2008

Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma

article

Genome instability is a consequence of transcription deficiency in patients with bone marrow failure harboring biallelic variants

article published in the Proceedings of the National Academy of Sciences of the United States of America

Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study

scientific article published on 16 May 2015

Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma

scientific article published on 9 May 2006

Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients

scientific article published on 01 May 2007

Liposomal cytarabine in cerebrospinal fluid.

scientific article

MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells.

scientific article

Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. ⬇️

scientific article published on 06 June 2017

Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience

scientific article

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. ⬇️

scientific article published on 9 December 2016

Sub-clonal copy number is associated with prognosis in multiple myeloma

scientific article published on 29 October 2018

Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE.

scientific article published on 6 August 2008

The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study.

scientific article published on 10 June 2010

The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone

scientific article published on 01 August 2007

The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a

scientific article published on 01 November 2006

Updates to the guidelines for the diagnosis and management of multiple myeloma

scientific article published on 7 May 2014

List of works by Matthew Jenner

A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).

Advances in oral therapy for multiple myeloma.

Deletions of CDKN2C in multiple myeloma: biological and clinical implications

Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma

Genome instability is a consequence of transcription deficiency in patients with bone marrow failure harboring biallelic variants

Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study

Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma

Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients

Liposomal cytarabine in cerebrospinal fluid.

MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells.

Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. ⬇️

Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. ⬇️

Sub-clonal copy number is associated with prognosis in multiple myeloma

Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE.

The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study.

The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone

The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a

Updates to the guidelines for the diagnosis and management of multiple myeloma